Could a sleep medication curb nicotine cravings?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants will be male and female volunteers between the ages of 18-50 * Participants must report daily smoking of at least 5 cigarettes per day over the last 6 months. * Participants must be nicotine dependent, having an FTND score greater than or equal to 4. * Participants must have an expired carbon monoxide level of 10 ppm or more on the screening day. * Participants must have an expired carbon monoxide level of no more than 10 ppm on the study visits. * Female participants must have a negative pregnancy test on all study days. Exclusion Criteria: * Participants cannot meet DSM-5 criteria for lifetime and/or current psychotic disorders such as bipolar disorder, schizophrenia, schizoaffective disorder * Participants cannot meet DSM-5 criteria for current substance abuse disorders other than nicotine and marihuana and cannot meet criteria for current moderate or severe alcohol use disorder (as assessed by the SCID-5) * Participants cannot have positive drug and alcohol screen on each study visit other than for nicotine or marijuana. * Participants reporting marihuana use greater than 1-2 times per week will be excluded. * Participants must report no marihuana use within 24 hours of the study visit. * Participants cannot be taking any prescription medication that could impact brain function including medications that depress CNS function * Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders. * Participants cannot be pregnant or breastfeeding. * Participants must be able to read screening materials including consent form and give informed consent * Individuals with severe hepatic impairment will be excluded. * Participants cannot be obese as determined by a Body Mass Index (BMI) of 30 or greater. * Participants cannot be using a CYP3A inhibitor/inducer (metabolism by CYP3A is the major elimination pathway for suvorexant) * Participants cannot have a current cardiac disorder such as palpitations, tachycardia and/or use of the cardiac medication Digoxin * Participants cannot have narcolepsy * Participants cannot self-report complex sleep behaviors such as sleep driving, preparing and eating food or making phone calls * Participants cannot have compromised respiratory function such severe obstructive sleep apnea or severe chronic obstructive pulmonary disease * Participants cannot have current major depressive disorder (within the past 6 months) and/or indorse suicidal ideation on the Beck Depression Inventory.